Tirzepatide GLP-2 Injection Vial (5mg, 10mg, 30mg)

Tirzepatide is a dual GIP and GLP-1 receptor agonist developed to target type 2 diabetes and obesity. Its dual action provides stronger metabolic control than GLP-1 agonists alone, making it one of the most studied incretin-based compounds.

Product Profile

• Compound: Tirzepatide

• Class: Dual GIP (glucose-dependent insulinotropic polypeptide) + GLP-1 (glucagon-like peptide-1) receptor agonist

• Form: Injectable vial

• Concentrations: 5mg, 10mg, 30mg

• Application: Laboratory and clinical research

Mechanism of Action

• GLP-1 activity: Increases insulin secretion, lowers glucagon release, slows gastric emptying, and reduces appetite.

• GIP activity: Enhances insulin sensitivity in adipose and muscle tissue, with additive effects on glucose metabolism.

• Combined incretin response: Produces greater reductions in body weight and blood sugar compared to GLP-1 alone.

Research Outcomes

Weight Reduction

• SURMOUNT-1 trial: Subjects achieved 15–21% body weight loss over 72 weeks.

• Example: A 100kg participant recorded reductions of 15–21kg depending on dose level.

Glycemic Control

• HbA1c reduced by 2.0–2.4% on average in type 2 diabetes patients.

• Outperformed Semaglutide 1mg in head-to-head trials by up to 0.5% additional HbA1c drop.

Metabolic & Cardiovascular Effects

• Lowered fasting insulin and triglycerides.

• Reduced cardiovascular event risk in obese and diabetic populations.

Pharmacokinetics

• Half-life: ≈ 5 days (120 hours), supporting weekly injections.

• Peak effect: Within 1–2 days post-injection.

5mg vs 10mg vs 30mg Vials

• 5mg vial: Entry dose, often used in early titration studies.

• 10mg vial: Mid-level dosing for steady metabolic effects.

• 30mg vial: High-dose research tier, linked to the largest reductions in weight and HbA1c in clinical trials.

Tirzepatide Research FAQs

1. What is Tirzepatide?
Tirzepatide is a dual incretin agonist activating both GIP and GLP-1 receptors, designed to improve weight loss and glycemic control.

2. What doses are available?
This product is supplied in 5mg, 10mg, and 30mg vials, allowing study at various titration levels.

3. How effective is Tirzepatide for weight loss?
Clinical data reports 15–21% total body weight reduction over 72 weeks of research cycles.

4. How fast does Tirzepatide work?
Appetite suppression is noticeable in the first 2–4 weeks, with significant weight loss typically documented after 8–12 weeks.

5. What is the half-life of Tirzepatide?
The compound has a half-life of ~5 days (120 hours), allowing for weekly dosing schedules.

6. How does Tirzepatide compare to Semaglutide?
Tirzepatide shows stronger weight reduction (≈5% more on average) and greater HbA1c decreases than Semaglutide in clinical trials.

7. What metabolic markers improve under Tirzepatide?

• HbA1c reduction: 2.0–2.4%

• Fasting insulin decline: measurable within 12 weeks

• Lower triglycerides and liver fat content

8. What are common side effects?
Gastrointestinal events, including nausea, vomiting, and diarrhea. Typically lessens after the first 4–6 weeks of dosing.

9. What cycle length is common in research?
Research trials often span 40–72 weeks, with dose titration every 4 weeks to reach higher levels.

10. Does Tirzepatide affect cardiovascular risk?
Yes. Research documents significant reductions in cardiovascular events in overweight and diabetic participants.

11. Can Tirzepatide increase insulin sensitivity?
Yes. Dual incretin activation enhances glucose uptake in muscle and lipid metabolism in adipose tissue.

12. What distinguishes 30mg vials from lower doses?
The 30mg vial supports high-dose protocols, which correlate with the greatest reductions in weight (20% or more) and HbA1c (≈approximately 2.4%).